ALSO NOTED: Korea blueprints bird flu vaccine factory;HIV researchers vow to pursue vaccine; and much more...

Vaccine Market

South Korea says it will build a bird flu vaccine factory next year. And the country says it will stockpile enough Tamiflu to be able to treat 10 million people in the event of a pandemic. The news comes as the virus forces authorities to decimate the country's poultry population. Report

A special federal court is hearing the second of three arguments laying out a claim that thimerosal triggered autism in thousands of cases. Article

Indian officials are investigating the deaths of three children following DPT vaccinations. Story

Vaccine Research

Alan Bernstein, executive director of the Global HIV Vaccine Enterprise, vowed that the scientific community is more determined than ever to develop a vaccine for HIV--despite recent setbacks. "I could not guarantee that one day we'll have a vaccine," Bernstein said. "But not to try is to say to all the 33 million people who are living with HIV worldwide, as well as the 2.3 million people who contract the virus every year, that researchers are 'giving up.' " Report

GeoVax Labs has struck a $10 million common stock purchase agreement with Fusion Capital Fund II, a Chicago-based institutional investor. Release

Sinobiomed is laying plans to launch a mid-stage study of its malaria vaccine candidate in epidemic areas. The study site is located in Thailand's Ratchaburi Province, approximately 200 km from Bangkok near the Myanmar border. Release

Population-based electronic immunization registries create the possibility of using registry data to conduct vaccine effectiveness studies which could have methodological advantages over traditional observational studies. Release

Dutch biotechnology company Crucell today announced that its rabies monoclonal antibody combination product has entered a second phase II clinical study in the Philippines. Release

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.